Posted: Tuesday, September 5, 2023
JNCCN–Journal of the National Comprehensive Cancer Network has published new research investigating survival outcomes among Asian versus White male patients with de novo metastatic prostate cancer. In a large, multiple-cohort study, Yao Zhu, MD, PhD, of Shanghai Cancer Center, and colleagues found better overall survival among Asian males across treatment regimens in all data sets examined. As a result, the researchers recommended that Asian race be considered an independent prognostic factor when evaluating patients’ prognoses, and they advocated further study to investigate the survival advantage observed.
“Our study is the most comprehensive analysis published to date on this topic and includes three of the largest extant data sets, with sufficient follow-up to analyze long-term outcomes across racial subgroups,” the investigators stated.
The study included a total of 27,041 male patients with de novo metastatic prostate cancer from three separate cohorts: LATITUDE clinical trial data (n = 1,199), the SEER (Surveillance, Epidemiology, and End Results) program (n = 15,476), and the National Cancer Database (n = 10,366). To adjust for known confounding variables, the investigators balanced patient-level data by propensity score matching before analyses. The primary outcomes studied were overall survival in the LATITUDE and National Cancer Database cohorts and both overall survival and cancer-specific survival in the SEER cohort. The research team observed better survival outcomes among Asian males versus White males across all three cohorts and all treatment regimens.
“This improvement in survival persists in subgroups receiving different kinds of systemic treatments including androgen-deprivation therapy, androgen-deprivation therapy plus abiraterone, and androgen-deprivation therapy plus chemotherapy,” the investigators noted. “These data…will help to further refine the prognosis of Asian and White males with metastatic prostate cancer…[and] will help improve planning for international trials in this disease space.”
Disclosure: For full disclosures of the study authors, visit jnccn.org.